UNIVERSAL-WELLNESS-LABS
5.5.2021 14:21:06 CEST | Business Wire | Press release
Digital Health Certificates are happening. Governments, airlines and the industry at large need solutions to get the people moving freely and safely. Universal Wellness Labs creates a wearable for hand cleaning that holds the QR-code for Health Certificates. The user-friendly gadget serves as an alternative medium, and as a back-up for the QR-codes in smartphone apps or printed on paper.
Health Certificates, a.k.a. Immunity Passports, Vaccine Certificates, Green Passes and PCR tests come as QR-code for storage in apps in people’s smartphones or printed on paper.
Universal Wellness Labs foresees potential issues and uses NFC as a medium for the QR.
It pairs the Health Certificate with hand hygiene in one useful and user-friendly wearable dispenser for hand sanitizer: the Zpritzi.
Marinus Vander Slikke, CEO of Universal Wellness Labs: “A document as vital as a Health Certificate must have a back-up. Apps can crash. Smartphones can die. Paper-printed QR-codes are old world, prone to forgery and get lost easily.”
NFC is secure, contactless and works without electronics and networks.
A video-presentation of the Zpritzi concept is available at www.zpritzi.com .
Universal Wellness Labs recently presented its concept to the European Commission.
Marinus Vander Slikke: “We anticipate deeper negotiations soon. Sweden and Denmark have already endorsed NFC. However, we are also targeting the private sector like airlines, hotels, cruise ships and event organisers.”
Zpritzi is a slim, elongated and ergonomic designed wearable gadget. Made from recyclable ABS. Refillable with any sanitizer spray. An integrated encrypted NFC tag stores the QR-code. People wear it around their neck, or on their belt or hand-bag.
Zpritzi is low-cost and an ideal product for corporate branding: It verifies people’s health status, makes hand disinfection easy and is a promotional tool with lasting marketing effects.
A pilot study with 88 participants shows the efficacy of the Zpritzi. Users clean their hands 75% more often with a Zpritzi than with conventional portable bottles.
Marinus Vander Slikke: “Hand cleaning is a first line of defence against any kind of bacteria and viruses, including Covid. Both the public and the private sector require proof of health to enter their country or premises. A quick scan of the Zpritzi verifies people’s health status. And the big advantage is that people always go in with clean hands.”
“In the new normal people still want to be trendy and look smart. Similar to face masks, Zpritzi makes the Health Certificate and hand sanitizing cool.”
Zpritzi is created in cooperation with Design2Gather, an award winning Dutch design company (design2gather.com ).
Universal Wellness Labs OÜ is an Estonia based company that conceptualizes and designs products for personal health and wellness (universalwellnesslabs.com ).
###
View source version on businesswire.com: https://www.businesswire.com/news/home/20210505005604/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom